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Abstract 
PET imaging studies using 5-HT1A receptor radiotracers show a decreased density of this receptor in 
hippocampi of patients with Alzheimer’s disease (AD) at advanced stages. However, current 5-HT1A 
receptor radiopharmaceuticals used in neuroimaging are antagonists, thought to bind to 5-HT1A 
receptors in different functional states (i.e., both the one which displays high affinity for agonists and 
is thought to mediate receptor activation, as well as the state which has low affinity for agonists). 
Comparing the PET imaging obtained using an agonist radiotracer, which binds selectively to 
functional receptors, with the PET imaging obtained using an antagonist radiotracer would therefore 
provide original information on 5-HT1A receptor impairment during AD. Quantitative autoradiography 
using [
18
F]F13640 and [
18
F]MPPF, a 5-HT1A agonist and antagonist, respectively, was measured in 
hippocampi of patients with AD (n=25, at different Braak stages) and control subjects (n=9). The 
neuronal density was measured in the same tissues by NeuN immunohistochemistry. The specific 
binding of both radiotracers was determined by addition of WAY-100635, a selective 5-HT1A receptor 
antagonist. The autoradiography distribution of both 5-HT1A PET radiotracers varied across 
hippocampus regions. The highest binding density was in the pyramidal layer of CA1. Incubation with 
Gpp(NH)p, a non-hydrolysable analogue of GTP, reduced significantly [
18
F]F13640 binding in 
hippocampal regions, confirming its preferential interaction with G-coupled receptors, and slightly 
increased [
18
F]MPPF binding. In the CA1 subfield, [
18
F]F13640 binding was significantly decreased at 
Braak stages I/II (-19%), Braak stages III/IV (-23%), and Braak stages V/VI (-36%) versus control. In 
contrast, [
18
F]MPPF binding was statistically reduced  only at the most advanced Braak stages V/VI 
compared to control (-33%). 
Since [
18
F]F13640 and [
18
F]MPPF can be used in vivo in humans, this neuropharmacological paradigm 
supports testing the concept of functional imaging using agonist radiopharmaceuticals in future 
clinical studies.  
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1. Introduction 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of 
extracellular amyloid plaques and intracellular neurofibrillary tangles, resulting from an abnormal 
aggregation of the amyloid beta-peptide and the hyperphosphorylated protein tau, respectively. In 
addition to these protein aggregates, the progressive loss of neurons and multiple neurotransmitter 
systems impairment represent the pathological hallmark of Alzheimer’s disease (Tampellini, 2015; 
Raskin et al, 2015). Although the loss of cholinergic fibers seems to be closely related to cognitive 
impairment, perturbations of other neurotransmitter systems may be involved in the 
pathophysiology of the disease. There is increasing evidence that the serotonergic system is highly 
dysfunctional in AD, which could be related to several clinical symptoms of dementia (Ramirez et al, 
2014). Many post-mortem studies have reported a loss of serotonin synthesizing neurons and 
modifications of serotonergic receptors densities in brains of AD patients (Halliday et al., 1992; Lorke 
et al., 2006; Salmon, 2007). In particular, several studies have shown a reduction of 5-HT1A receptors 
levels (Bowen et al., 1989; Cross et al., 1988; Middlemiss et al., 1986). Serotonergic 5-HT1A receptors 
are of particular interest since they are strongly expressed in the hippocampus, which is heavily 
involved in functions such as memory, behavior and emotions (Albert et al, 2014; Borg, 2008; Sarnyai 
et al., 2000). Although several 5-HT1A-targeting molecules have been proposed to treat cognitive or 
non-cognitive symptoms in AD, results have been inconsistent and converging preclinical and clinical 
data are still awaited to validate this receptor as a therapeutic target in AD (Schechter et al., 2005; 
Sato et al., 2007; Depoortere et al., 2010). Notably, precise links between 5-HT1A receptors and 
cognition remains to be elucidated to validate this target for treatment of cognitive deficits (Borg, 
2008; Ramirez, 2014). Because the earliest severe cognitive deficit in AD concerns episodic memory 
linked to neurofibrillary tangles in the hippocampus (Dubois et al., 2007; Serrano-Pozo et al., 2011), 
several studies have focused on 5-HT1A receptor status in the hippocampus of AD living patients by 
Positron Emission Tomography (PET) imaging. Using the radiolabeled antagonist [
18
F]MPPF, these 
studies have shown a decrease of 5-HT1A receptor density in the hippocampus of advanced AD 
patients (Kepe et al., 2006; Lanctôt et al., 2007). On the contrary, an up-regulation of 5-HT1A 
receptors has been reported at the Mild Cognitive Impairment (MCI) stage, prodromal of AD (Truchot 
et al., 2007; Truchot et al., 2008). The pathophysiological significance of this phenomenon remains to 
be elucidated, and could reflect compensatory mechanisms occurring at the earliest stages of this 
neurodegenerative disease (Truchot et al., 2007; Verdurand et al., 2011). 
An improved understanding of the functional role of 5-HT1A receptors in AD may be gained by 
taking into account additional aspects of their pharmacological profile. Indeed, as G-protein-coupled 
receptors (GPCR), they have been shown to exist in different states (Mongeau et al., 1992; Nénonéné 
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et al., 1994): a high-affinity state for agonists, (effective receptor/G-protein coupling, supposedly 
active), and a low affinity (G-protein uncoupled, non-functional). Contrary to an agonist, an 
antagonist, like [
18
F]MPPF used in previous PET studies, indiscriminately labels all 5-HT1A receptors, 
regardless of their G-protein coupling state (Gozlan et al., 1995; Burnet et al., 1997). Furthermore, 
growing evidence suggests that changes in receptor/G-protein coupling may be involved in 
neurodegenerative disorders (Thathiah and De Strooper, 2011). It has to be noted that the functional 
(G-protein coupling) state of receptors has not been taken into account in the interpretation of 
previous PET study data, particularly in AD patients. Therefore, comparing the 5-HT1A receptor 
binding detected by antagonist and agonist PET radioligands could provide additional information 
concerning the proportion of “functional receptors” during AD (Figure 1).  
The aim of this study was to investigate the modifications of 5-HT1A receptor coupling in 
human brain during AD, using autoradiography on post-mortem hippocampus sections. We 
compared on the same patients the binding profiles of [
18
F]F13640, a highly selective 5-HT1A 
receptors ‘full agonist’ currently evaluated in a first-in-man study as a PET radiopharmaceutical (Vidal 
et al., 2014; EU Clinical Trials Register, EudraCT number #2016-00016-15), and of [
18
F]MPPF, a 5-HT1A 
receptors antagonist which has already been widely used in clinical PET studies (Cheng, 2005; 
Aznavour and Zimmer, 2007). We hypothesized that we would observe different modifications 
between the “total” and “coupled” 5-HT1A receptors states over the course of the disease, supporting 
the use of 5-HT1A receptor agonists in PET imaging of neurodegenerative disorders. As some studies 
interpreted 5-HT1A receptor changes in terms of neuronal density (Bowen et al., 1989; Kepe et al., 
2006; Lanctot et al., 2007), we also investigated the number of pyramidal cells in the same brain 
areas by NeuN immunohistochemistry. 
 
 
2. Methods 
 
2.1. Subjects and tissue samples 
Fresh frozen hippocampus sections were obtained from the MRC London Neurodegenerative 
Diseases Brain Bank after approval by the brain bank’s scientific review committee. Brain tissue of 34 
subjects were included, with 9 control subjects, 5 Braak I-II subjects, 10 Braak III-IV subjects and 10 
Braak V-VI subjects (Table 1). Patient ages, post-mortem delay and sex ratio were not significantly 
different among the patient groups (all p>0.05). The Braak staging was based on assessment of 
immunohistochemically labeled hyperphosphorylated tau immunoreactive neuropil threads, 
according to the BrainNet Europe consortium (Alafuzoff et al., 2008). Stage 0 was characterized by a 
total absence of neurofibrillary pathology and was used as control group; stages I, II, and III had 
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changes confined to the transentorhinal and entorhinal regions, and a beginning of AT8 
immunopositive neurofibrillary tangles in temporal and temporo-occipital cortices; stages IV, V, and 
VI had marked destruction of these regions, extending to isocortical association areas, namely the 
occipital cortex. Each case included 15 successive hippocampus sections of 30 µm thickness. The 
sections were stored at -80°C without formalin fixation for autoradiography experiments (two 
sections per slide).  
 
2.2. Radiosyntheses and quality controls 
On the days of autoradiography experiments, [
18
F]MPPF and [
18
F]F13640 were synthesized in an 
automated radiosynthesizer (Neptis, ORA) according to previously described radiochemical pathways 
(Le Bars et al., 1998; Vidal et al., 2014). Their chemical and radiochemical purities, as measured by 
HPLC, were higher than 98%. The specific activity at time of autoradiography was calculated at 37 
GBq/µmol (1 Ci/µmol) for [
18
F]MPPF, and 11.1 GBq/µmol (0.3 Ci/µmol) for [
18
F]F13640. 
 
2.3. Quantitative 5-HT1A receptors autoradiography 
Defrosted slides were incubated for 20 min in Tris phosphate-buffered saline buffer (138 mM NaCl, 
2.7 mM KCl, pH adjusted to 7.5) containing 37 kBq/mL (1 µCi/mL) of [
18
F]MPPF or [
18
F]F13640. For 
each radioligand, the specific activity was calibrated so that the concentration added in the buffer 
was equal to three times the Kd. Thus, the sections were incubated with either 1 nM of [
18
F]MPPF or 
3 nM of [
18
F]F13640, with known Kd of 0.3 nM and 1 nM, respectively (Kung et al., 1996; Maurel et al, 
2007). Non-specific binding was determined in duplicate serial sections co-incubated with 10 µM 
WAY-100635 (Sigma-Aldrich). For verification of the agonistic binding of [
18
F]F13640, the 
corresponding buffer was supplemented with Gpp(NH)p (10 µM), a non-hydrolysable analogue of 
GTP that elicits decoupling of G-protein-coupled receptors. After incubation, the slides were dipped 
in cold buffer and distilled water (4°C), then dried and juxtaposed to a phosphor imaging plate for 60 
min (BAS-5000, Fujifilm). All films were analyzed by a computer-assisted image analysis system 
(Multigauge, Fujifilm), and regions of interest (CA1, dentate gyrus) were drawn manually, according 
to a human brain atlas (Mai and Paxinos, 1997) and confirmed by a following Luxol-Fast Blue staining 
and by a NeuN immunostaining (procedure described below). Quantitation in each region of interest 
was performed by measuring the average optical density in the adjacent brain sections. In parallel, 
calibration standards were prepared from rat brain tissue homogenates, following the same 
procedure described in our previous post-mortem study (Becker et al., 2014). Briefly, rat brains were 
extracted, homogenized and their mass was determined after aliquoting in micro-vials before 80°C 
congelation. Their protein content was quantified using a chemistry analyzer (Architect Ci8200, 
Abbott Diagnostics). On the day of experiment, increasing activities of radioligand were mixed with 
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these homogenates, which were then immediately frozen and cut into 30 µm coronal section. These 
extemporaneous standards were juxtaposed to the same imaging plates used for the human tissue, 
and signal to concentration curves were generated. Non-specific binding was subtracted from the 
total binding to determine the specific binding, and measurements were converted into fmoles of 
ligand/mg of protein, according to the calibration curve obtained from the standards.  
 
2.4. NeuN immunostaining and neuron counting 
One slide per subject was processed for immunohistochemistry using a mouse monoclonal antibody 
directed against the neuron-specific nuclear antigen NeuN (mAB377 A60, Chemicon, 1/500). Images 
of the entire sections were taken using a slide scanner (Zeiss Axioscan, CIQLE microscopy platform, 
Lyon). The whole images were used to validate the regions of interest (ROIs) delimitation on the 
autoradiographs and to estimate neuronal densities (Figure 2). NeuN-positive cells were manually 
counted in the CA1 area using the ImageJ cell counter (Schneider et al., 2012). Each counting was 
done by two different experimenters who were blind for the subjects’ groups. In the dentate gyrus, 
cells were automatically counted by the Icy software (tool “Spot detector”), by applying pre-defined 
counting parameters. Some subjects were excluded from this part of the study because the detected 
spots did not match with the NeuN-positive cells. In both regions of interest, the result was 
expressed in number of neurons per mm
3
. 
 
2.5. Statistical analyses 
Demographics were compared among the groups using the Kruskal-Wallis non parametric test. 
Statistically significant variations in radioligand binding and neuronal density, for each Braak stage 
versus control, were measured by Mann-Whitney non parametric test. For all the analyses, the 
statistical significance was set at p<0.05 (GraphPad Prism6). 
 
 
3. Results 
 
3.1. Autoradiography 
The autoradiography distribution of both 5-HT1A receptors radiotracers varied across the 
hippocampus sub-regions (Figure 1). The highest binding density was found in the pyramidal cell 
layer of CA1, whereas it was moderate in the dentate gyrus and CA3, consistent with previous 
findings (Burnet et al., 1995; Becker et al, 2014). The addition of the 5-HT1A receptors antagonist 
WAY-100635 at 10 µM in the buffer resulted in a 85 to 90% decrease of [
18
F]F13640 and [
18
F]MPPF 
binding, confirming their 5-HT1A receptor specificity. The addition of Gpp(NH)p in the buffer led to a 
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70% decrease of the [
18
F]F13640 binding. In the same conditions, a slight increase of [
18
F]MPPF 
binding was measured after addition of Gpp(NH)p (+17%) (see Figure 3). 
Comparison of [
18
F]F13640 and [
18
F]MPPF binding identified different modifications of 5-HT1A 
receptor density according to the Braak stages, and depending on the hippocampal subfield 
considered (Figure 4). In the CA1 subfield, [
18
F]F13640 binding was significantly decreased at Braak 
stages I/II (-19%; p<0.05), Braak stages III/IV (-23%; p<0.05), and Braak stages V/VI (-36%; p<0.01) 
versus control. In contrast, [
18
F]MPPF binding was statistically reduced  only at the most advanced 
Braak stages V/VI compared to control (-33%; p<0.01). In the dentate gyrus, [
18
F]MPPF labeling was 
unchanged at late stages compared to control, but significantly increased at the early stages Braak 
I/II (+26%; p<0.05). On the contrary, [
18
F]F13640 binding was unchanged at these same stages, but 
strongly decreased at Braak stages V/VI (-40%; p<0.01).  
 
3.2 Neuron counting 
In the CA1 subfield, the neuronal density quantified by NeuN immunohistochemistry was unchanged 
in the AD patients versus the control group, until the latest Braak stages V/VI (-38%; p<0.05). In the 
dentate gyrus, it was unchanged at advanced Braak stages but increased in the early Braak stages I/II 
(+53%; p<0.05; see Figure 2). 
 
 
4. Discussion 
 
The neuropharmacological hypothesis of our study was that the agonist radiotracer 
[
18
F]F13640, that preferentially labels G-protein-coupled 5-HT1A receptors, would detect a different 
profile of 5-HT1A receptors modifications during AD in comparison to the antagonist radiotracer 
[
18
F]MPPF which labels the entire 5-HT1A receptors population. Both radiotracers are highly selective 
for 5-HT1A receptors, with a comparable nanomolar affinity (Kung et al., 1997; Colpaert et al., 2002). 
The agonist properties of [
18
F]F13640 and its selectivity for G-protein-coupled functional receptors, 
previously described in rat brain (Vidal et al, 2014), were confirmed by the uncoupling action of 
Gpp(NH)p which decreased sharply the radiotracer binding in human tissues. Conversely, under 
similar conditions, the binding of the antagonist [
18
F]MPPF was slightly increased in the presence of 
Gpp(NH)p, confirming previous studies (Lemoine et al, 2010). In a recent study, we proposed that the 
coupling state of 5-HT1A receptors was altered before the loss of receptors themselves in AD (Becker 
et al., 2014). However, this previous study was preliminary since the number of patients was small. 
Moreover, neuronal density was not determined and the agonist radiotracer we used, [
18
F]F15599, is 
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not developed as a clinical research PET radiopharmaceutical, limiting the translational impact of the 
results.  
As detailed above, the present study was carefully designed to ensure the validity of results, 
supported by a robust methodology. (i), for each radioligand and for each radiosynthesis, samples 
from all 34 patients were tested simultaneously to avoid inter-variability between radiosyntheses or 
between autoradiography films; (ii), the normalization of the results was improved by the use of 
calibration curves enabling the quantification of the binding intensity in fmoles of radioligand per 
gram of tissue; (iii), for each radioligand, the specific activity and the incubation concentration were 
calibrated so that the concentration added in the buffer was equal to three times the Kd, to ensure 
optimal saturating concentrations (Burnet et al., 1997); (iv), the fact that the agonist [
18
F]F13640 
binds preferentially to G-protein-coupled ‘functional’ 5-HT1A receptors was confirmed by the 
receptor/G-protein decoupling action of Gpp(NH)p; (v);  for each patient, serial sections were used, 
limiting inter-individual variability;  (vi), in terms of patient stratification, the Braak staging was used 
to sort patients by degree of Tau pathology as it has been demonstrated that there is a good 
correlation between hyperphosphorylated tau deposits and the cognitive status (Braak and Braak, 
1991; Alafuzoff et al., 2008); (vii), the different patient groups were well-matched in terms of age and 
post-mortem delay, an important point to consider since these demographic values are known to 
potentially impact the G-protein coupling state of receptors (Gonzalez-Maeso et al., 2002). However, 
as is frequent in studies using brain bank tissues, it should be noted that we did not have access to 
the clinical data relative to the pre-mortem psychiatric status and the possible psychotropic drugs 
taken by each patient.   
In the CA1 subfield of hippocampus, the [
18
F]MPPF binding, reflecting the total number of 5-
HT1A receptors, was decreased in the latest Braak stages V/VI compared to control, which is 
consistent with the literature. In particular, an immunohistochemical study showed very similar 
results, with a 5-HT1A receptor loss specifically observed in CA1 and only in Braak stages V/VI 
(Mizukami et al., 2011). Although most of the other post-mortem studies also showed a decrease in 
5-HT1A receptors in AD patients’ brain (Bowen et al., 1989; Francis et al., 1993; Cross et al., 1988), the 
neuropathological status of the patients was not systematically taken into account. Similarly, several 
PET imaging studies of 5-HT1A receptors reported a decrease of [
18
F]MPPF binding in the 
hippocampus of patients with advanced AD, but results were divergent at predementia stages (Kepe 
et al., 2006 ; Lanctot et al., 2007 ; Truchot et al., 2007). Taken together, these results are in favor of a 
modest decrease of 5-HT1A receptors density in AD, in several areas including the hippocampus, and 
measurable at the advanced stages of the disease.  
Interestingly, in the case of [
18
F]F13640 binding (reflecting the functional population of 5-HT1A 
receptors), a significant decrease was detected at an earlier Braak stage, i.e. in all AD groups 
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including the early Braak stages I/II. These findings support the occurrence of an early uncoupling of 
5-HT1A receptors in the CA1 subfield, prior to the loss of receptors themselves, when neurofibrillary 
tangles are sparsely detectable in the hippocampus (Raskin et al, 2015). Other studies also suggested 
that GPCR function is altered during AD (Thathiah and De Strooper 2011), especially in the CA1 
subfield (Garcia-Jimenez et al., 2002), and including/affecting 5-HT1A receptors (Weinstein et al 
1996). The pathophysiological meaning of this 5-HT1A receptors uncoupling in CA1 remains to be 
investigated but we can hypothesize that it might lead to an impaired intracellular signaling prior to 
the apparition of clinical signs (Garcia-Jimenez et al., 2002).  
Another observation we made was that, compared to other hippocampal subfields, CA1 was 
particularly affected by both loss of 5-HT1A receptors at the latest Braak stages (detected by 
[
18
F]MPPF labeling) and uncoupling of 5-HT1A receptors at the early stages (detected by [
18
F]F13640 
labeling). This observation could result from the stronger density of 5-HT1A receptors in CA1, making 
changes in this hippocampal subfield more easily detectable. Additionally, this subfield may be 
particularly vulnerable to AD processes (Garcia-Jimenez et al., 2002; Mizukami et al., 2011; De Flores 
et al., 2015).  
In the dentate gyrus, the [
18
F]F13640 signal was decreased only in the Braak V/VI group 
compared to the control one, and no reduction of [
18
F]MPPF binding was observed in this area during 
disease progression. On the contrary, there was a significant increase of [
18
F]MPPF signal in the Braak 
I/II group. This surprising result is quite similar to previous findings from in vivo PET studies which 
reported an increase of [
18
F]MPPF binding in the hippocampus at an early stage of the disease in MCI 
patients (Truchot et al, 2007). This observation was also replicated in our laboratory in a rodent 
model of AD where the infusion of the amyloid beta-40 peptide in the rat hippocampus induced a 
transient 5-HT1A receptors overexpression specific to the dentate gyrus (Verdurand et al, 2011; 2016). 
Such an early increase in hippocampal [
18
F]MPPF binding may be explained by the transient 
hippocampal hyperactivity that has been extensively observed in MCI patients in terms of cholinergic 
neurotransmission (DeKosky et al, 2002), fMRI activation (Dickerson et al,  2004; 2005) or glucose 
metabolism (Tahmasian et al, 2015). It is mainly interpreted as a compensatory mechanism that 
would later be challenged by disease progression at the dementia stage. Therefore, the 5-HT1A 
receptors transient “rebound” in the hippocampus may be another sign of this hyperfunction. 
Importantly, we did not observe such increase in the dentate gyrus with the agonist [
18
F]F13640, 
which would mean that the overexpressed 5-HT1A receptors are in a non-functional state. Therefore, 
the pathophysiological link between this phenomenon and possible compensatory mechanisms is 
unclear. Since this serotonergic hyperactivity seems specific to the dentate gyrus, it could be linked 
to the neurogenesis that occurs in this hippocampal sub-region (Verdurand et al., 2016). The 
possibility of increased hippocampal neurogenesis during AD is nonetheless still a matter of debate 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
10 
 
(Mu and Gage, 2011; Jin et al., 2004; Donovan et al., 2006). This early serotonergic hyperactivity 
could also be due to an astrocytic reaction, which has been reported in pre-senile AD cases and 
animal models (Boekhoorn et al., 2006; Verdurand et al., 2011) and may reflect astrocyte expression 
of 5-HT1A receptors in their inactive state (Hirst et al., 1998) (although other studies have questioned 
astrocytic localization of 5-HT1A receptors (Kia et al., 1996)). More recently, increased hippocampal 
activation in MCI has also been hypothesized to be a dysfunctional condition instead of a beneficial 
functional compensation (Bakker et al., 2012; Tahmasian et al., 2015). Indeed, 5-HT1A receptors are 
coupled to Gi/o proteins for signal transduction, and their activation in hippocampus results in 
adenylyl cyclase inhibition and GIRK activation which strongly inhibits the neuronal firing and 
excitability (Polter and Li, 2010). An early loss of 5-HT1A receptors functionality could therefore 
indirectly contribute to a greater and potentially harmful hippocampal activity.  
In several previous PET imaging studies, the total density of 5-HT1A receptors (as measured by 
an antagonist radioligand) was interpreted as an indirect marker of neuronal density, therefore 
providing a convenient way to estimate the pyramidal cells loss in the living brain of AD patients 
(Kepe et al., 2006; Bowen et al 1989; Mizukami et al 2011). In our study, we quantified the pyramidal 
neurons on adjacent slides using NeuN immunostaining in order to evaluate the relationship 
between neuronal density, total 5-HT1A receptors, and functional receptors. In the CA1 area, we only 
found a significant decrease of neuronal density in the Braak V/VI group, although there was a 
downward trend in the Braak I/II group. In the dentate gyrus, the neuronal density was significantly 
increased in the Braak I/II group and unchanged in the other groups. Interestingly, in both regions, 
these longitudinal modifications paralleled those observed with [
18
F]MPPF binding. In agreement 
with previous findings (Kepe et al., 2006; Mizukami et al., 2011), our observations suggest that the 
total density of 5-HT1A receptors in the hippocampus (regardless of their coupling state) is related to 
the neuronal density. Interestingly, in the CA1 hippocampal subfield, [
18
F]F13640 binding clearly 
appeared to be decreased earlier and to a greater extent than the neuronal loss. The functional 
impairment of 5-HT1A receptors might therefore be related to the presence of neurofibrillary tangles 
rather than to decreases in neuronal density.  
Finally, the results of this in vitro study have a strong translational transferability. We 
demonstrated the hypothesis that agonist and antagonist radiotracers bind differently to 5-HT1A 
receptors in human brain tissue, revealing distinct GPCR coupling states. The extent of 5-HT1A 
receptor G-protein coupling may provide original information to understand mechanisms underlying 
neurotransmission impairment during Alzheimer’s disease. We chose fluorinated 5-HT1A receptors 
radioligands which are directly transferable to PET imaging in vivo: the antagonist [
18
F]MPPF is a 
widely-used PET radiopharmaceutical and the agonist radiotracer we developed, [
18
F]F13640, will 
soon be available for human studies because its first-in-man study is in progress  (EU Clinical Trials 
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Register, EudraCT number #2016-00016-15). The present results therefore support a new 
neuropharmacological concept for nuclear medicine consisting in comparing the binding profiles of a 
PET agonist and an antagonist in subjects to determine in vivo the extent of G-protein coupling of 5-
HT1A receptors and to follow its modifications in functionality during the neurodegenerative process. 
More widely, this concept could also be explored in other neuropsychiatric diseases involving 
changes in 5-HT1A receptor expression and function and in the exploration of their respective 
therapeutics. 
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Table 1. Demographic data of the patients 
 
 
 Braak stages Control I/II III/IV V/VI 
 
Number of cases 
9 5 10 10 
Age (years) 79.3 ± 12.1 84.2 ± 8.8 83.5 ± 6.9 75.5 ± 12.0 
Gender (M/F) 6/3 2/3 5/5 7/3 
Postmortem interval (h) 35.8 ± 12.7 36.1 ± 10.5 35.2 ± 18.1 41.4 ± 23.0 
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Figure 1. Regional distribution of [
18
F]F13640 and [
18
F]MPPF binding sites in the hippocampus of a 
control subject (DG, dentate gyrus; CA1, CA1 area on the corresponding anatomic slice modified from 
Duvernoy et al., 2005). 
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Figure 2. Regional density of NeuN in the hippocampus of control subject (entire image obtained by a 
slide scanner; same patient as shown in Figure 1). Boxes highlight areas where neuronal densities 
were measured: (A), CA1 area; (B) dentate gyrus area. 
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Figure 3. Differential effects of Gpp(NH)p, decoupling receptors from G proteins, on the two 5-HT1A 
receptors radiotracers. The antagonist [
18
F]MPPF binds to all 5-HT1A receptors, both in a G-protein 
coupled receptor state and uncoupled state. The agonist [
18
F]F13640 binds mostly to the G-protein 
coupled receptor state (functional receptors). (A) Autoradiographs showing the decrease of 
[
18
F]F13640 binding when Gpp(NH)p is added during incubation, both in a control subject (left slices) 
and in an AD subject (right slices). (B) Autoradiographs showing the light increase of [
18
F]MPPF 
binding when Gpp(NH)p is added during incubation, both in a control subject (left slices) and in an AD 
subject (right slices). (C) Quantification of [
18
F]F13640 binding in the hippocampus after Gpp(NH)p 
decoupling (n = 18 subjects) : -59% in the dentate gyrus (DG) and -75% in CA1 area (CA1), both at 
p<0.001 with one-sample t-test. (D) Quantification of [
18
F]MPPF binding in the hippocampus after 
Gpp(NH)p decoupling (n = 16 subjects) : +17% in the dentate gyrus (p<0.01) and + 18% in CA1 
(p<0.001), one-sample t-test.  
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Figure 4. Neuronal density (as revealed by NeuN immunostaining) and 5-HT1A receptor binding site 
densities (according to the [
18
F]MPPF and [
18
F]F13640 binding in the dentate gyrus and CA1 areas of 
Alzheimer’s disease patients at different Braak stages. Results are expressed as a percentage of the 
control group (Braak stage 0). *p<0.05; **p<0.01, Mann-Whitney nonparametric t-test. 
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Highlights  
• 5-HT1A receptor autoradiography was performed in hippocampi of AD patients. 
• Two 5-HT1A PET ligands were compared: an agonist, [
18
F]F13640, vs an antagonist, [
18
F]MPPF. 
• [
18
F]F13640 labels specifically G-coupled receptors, i.e. the functional receptors. 
• [
18
F]MPPF labels all 5-HT1A receptors, regardless of their G-protein coupling state. 
• Comparison of these distinct bindings is proposed as new neuropharmacological paradigm 
for PET. 
